{"id":"W4406160646","doi":"10.1016/s0140-6736(24)02575-3","title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":251,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Hepatocellular carcinoma; Placebo; Internal medicine; Oncology; Double blind; Carcinoma; Sorafenib; Immunotherapy; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001352303,0.001811617,0.003569447,0.0004568488,0.0003590062,0.00118467,0.0009669919,0.001650136,0.006154663],"category_scores_gemma":[0.001181224,0.0008088301,0.001916071,0.0004899928,0.001228993,0.001281141,0.0004304284,0.003471969,0.001336307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008125447,"about_ca_system_score_gemma":0.0008604156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001276652,"about_ca_topic_score_gemma":0.002189071,"domain_scores_codex":[0.9995215,0.000243943,0.0000223741,0.00009129056,0.00003215636,0.00008873173],"domain_scores_gemma":[0.9993994,0.0001700712,0.0001258029,0.00005700469,0.00003210139,0.000215677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9804187,0.0042559,0.0002133241,0.0004822856,0.0009001899,0.00002401744,0.00002785182,0.0001980156,0.002460168,0.0000574509,0.0004346216,0.01052744],"study_design_scores_gemma":[0.9340979,0.06308489,0.001251774,0.0000228807,0.0004963066,0.00002457486,0.00001980687,0.0002385732,0.0003603047,0.00008227574,0.0003068442,0.00001385723],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876764,0.005955283,0.0007812532,0.0007883175,0.0007086815,0.001405807,0.0007505768,0.0001551413,0.001778561],"genre_scores_gemma":[0.9856866,0.00363037,0.001302536,0.001064015,0.0005498992,0.00227054,0.0007781921,0.00003631304,0.004681591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006154663,"threshold_uncertainty_score":0.02058935,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1038831164175795,"score_gpt":0.3283258552258007,"score_spread":0.2244427388082212,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}